Clinical and Translational Oncology

, Volume 14, Issue 9, pp 689–697

Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

  • Carlos Gómez-Martin
  • Antonio Sánchez
  • Antonio Irigoyen
  • Beatriz Llorente
  • Begoña Pérez
  • Raquel Serrano
  • Mª José Safont
  • Esther Falcó
  • Adelaida Lacasta
  • Margarita Reboredo
  • Jorge Aparicio
  • Rosario Dueñas
  • Marta Llanos Muñoz
  • Pilar Regueiro
  • Elena Sanchez-Viñes
  • Rafael López López
Research Article

DOI: 10.1007/s12094-012-0858-3

Cite this article as:
Gómez-Martin, C., Sánchez, A., Irigoyen, A. et al. Clin Transl Oncol (2012) 14: 689. doi:10.1007/s12094-012-0858-3

Abstract

Introduction

Hand–foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.

Materials and methods

This phase II, multicenter, non-controlled study assessed the safety, particularly grade three HFS incidence, and efficacy of four capecitabine-based chemotherapy regimens [cisplatin/capecitabine (CX), epirubicin/cisplatin/capecitabine (ECX), epirubicin/oxaliplatin/capecitabine (EOX) and docetaxel/cisplatin/capecitabine (DCX)] as first-line treatment for advanced and/or metastatic gastric cancer.

Results

One hundred and eight patients were assigned to one of the four treatment groups, according to investigator’s criteria, and grouped together for both safety and efficacy primary analyses. HFS was reported in 31 patients (19.6 %) and its first presentation occurred at a median of 72 days (range 19–209 days). Grade 3 HFS developed in 6.3, 5.2, 3.7 and 2.4 %, of patients receiving ECX, DCX, EOX or CX chemotherapy regimen, respectively. Capecitabine dose reduction/discontinuation due to HFS was required in 5.7 % of patients (9/158). The most common (>10 %) grade 3–4 treatment-related AEs were neutropenia (15.2 %), asthenia (12.0 %) and diarrhoea (11.4 %).

Conclusions

A moderate incidence of HFS was reported in patients treated with capecitabine, which generally presented late and required dose reduction in <1/3 of patients. The results suggest that capecitabine may be useful in combination with standard fluorouracil-based regimens in patients with advanced and/or metastatic gastric cancer with favourable safety profile.

Keywords

Capecitabine stomach neoplasmsNeoplasm metastasisFluorouracilFoot dermatoses/chemically inducedHand dermatoses/chemically induced

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012

Authors and Affiliations

  • Carlos Gómez-Martin
    • 1
    • 16
  • Antonio Sánchez
    • 2
  • Antonio Irigoyen
    • 3
  • Beatriz Llorente
    • 4
  • Begoña Pérez
    • 5
  • Raquel Serrano
    • 6
  • Mª José Safont
    • 7
  • Esther Falcó
    • 8
  • Adelaida Lacasta
    • 9
  • Margarita Reboredo
    • 10
  • Jorge Aparicio
    • 11
  • Rosario Dueñas
    • 12
  • Marta Llanos Muñoz
    • 13
  • Pilar Regueiro
    • 14
  • Elena Sanchez-Viñes
    • 14
  • Rafael López López
    • 15
  1. 1.Gastrointestinal Cancer Unit, Medical Oncology DivisionDoce de Octubre University HospitalMadridSpain
  2. 2.Oncology DepartmentPuerta de Hierro University HospitalMadridSpain
  3. 3.Oncology DepartmentVirgen de las Nieves HospitalGranadaSpain
  4. 4.Medical Oncology DepartmentGeneral Yagüe HospitalBurgosSpain
  5. 5.Oncology DepartmentVirgen del Rocío HospitalSevillaSpain
  6. 6.Oncology DepartmentReina Sofía HospitalCórdobaSpain
  7. 7.Oncology DepartmentGeneral Hospital of ValenciaValenciaSpain
  8. 8.Oncology DepartmentSon Llatzer HospitalPalma de MallorcaSpain
  9. 9.Oncology DepartmentDonostia HospitalDonostiaSpain
  10. 10.Oncology DepartmentJuan Canalejo HospitalA CoruñaSpain
  11. 11.Oncology DepartmentLa Fé HospitalValenciaSpain
  12. 12.Oncology DepartmentHospital of JaenJaenSpain
  13. 13.Oncology DepartmentUniversity Hospital of CanariasSanta Cruz de TenerifeSpain
  14. 14.Medical DepartmentRoche FarmaMadridSpain
  15. 15.Oncology DepartmentComplejo Hospitalario Universitario of SantiagoSantiago de CompostelaSpain
  16. 16.Gastrointestinal Cancer Clinical Research Unit, Clinical Research ProgrammeSpanish National Câncer Research Centre (CNIO), Fuenlabrada University HospitalMadridSpain